PCA
KERX

Prospect Capital Advisors’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Prospect Capital Advisors’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-149,745
Closed -$696K – 30
2017
Q4 		$696K Hold
149,745
– – 0.44% 23
2017
Q3 		$1.06M Hold
149,745
– – 0.57% 24
2017
Q2 		$1.08M Buy
149,745
+49,745
+50% +$311K 0.59% 22
2017
Q1 		$616K Buy
+100,000
New +$548K 0.43% 21

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Prospect Capital Advisors's KERX Position: Q1 2018 in Review

Prospect Capital Advisors sold out of Keryx Biopharmaceuticals Inc (KERX) in Q1 2018, closing a stake of 149,745 shares — an estimated $696K sold.

Prospect Capital Advisors first reported a position in KERX in Q1 2017 and held it in 4 quarters. The position peaked at $1.08M in Q2 2017. 125 funds tracked by Wall St. Rank hold KERX as of Q1 2018.

  • Prospect Capital Advisors reported no remaining Keryx Biopharmaceuticals Inc position as of Q1 2018 after selling out during the quarter.
  • Prospect Capital Advisors sold 149,745 Keryx Biopharmaceuticals Inc shares in Q1 2018, an estimated $696K.
  • Prospect Capital Advisors first reported a position in Keryx Biopharmaceuticals Inc in Q1 2017 and held it in 4 quarters.
  • Prospect Capital Advisors's Keryx Biopharmaceuticals Inc position peaked at $1.08M in Q2 2017.
  • 125 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q1 2018.

Based on Prospect Capital Advisors's 13F filing for Q1 2018, filed 15 May 2018.